Omeros Corporation To Introduce Its Proprietary T-CAT(TM) Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Stock Information for Omeros Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Omeros Corporation

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)
Omeros Corporation Reports Third Quarter 2025 Financial Results
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025
Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group
Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program
Omeros Corporation Reports Second Quarter 2025 Financial Results
Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025
Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.